title: [The radiochemotherapy of the oesophageal cancer].
abstract: OBJECTIVE
  To prove the efficacy of the simultaneous radio-chemotherapy of the inoperable or non-resectable esophageal cancer.
  
  
  METHODS
  Twenty-nine patients with inoperable or non-resectable oesophageal cancer were treated between January 1995 and December 2002. The therapy was started with intraluminal HDR AL irradiation for the recanalisation of the esophagus (8 Gy at 0.5 cm depth, repeated two-three times, with one-week interval), followed by percutaneous megavolt irradiation one week after the last HDR AL session (50 Gy total dose, 5 x 2 Gy/week fractions for 5 weeks). The chemotherapy was started simultaneously with the percutaneous megavolt irradiation (three courses of Cisplatin-5-Fluorouracil combination, with four-week intervals).
  
  
  RESULTS
  The swallow function has been improved in 16/29 patients, it remained unchanged in 10/29 and got worse in 3/29 patients (1 and 3 Units), respectively. REMISSION: complete 9/29 patients, partial 17/29 patients. Side effects: Esophagitis of different degree occurred in all patients, consecutive transitory dysphagia developed in 8/29 patients, leucopenia after the chemotherapy in 2/29 patients, tracheo-esophageal fistula in 3/29 patients. Follow-up time: average 12.2 months (3-55 months). The duration of the swallow function improvement: average 10.7 months (2-55 months).
  
  
  CONCLUSIONS
  The initial results refer to the favourable effect of the palliative radio-chemotherapy of the inoperable esophageal cancer.
authors.affiliation: Fôvárosi Onkoradiológiai Központ, Fôvárosi Onkormányzat Uzsoki utcai Kórháza, Budapest 1145, Hungary.
authors.forename: Péter
authors.initials: P
authors.lastname: Patonay
authors.forename: Attila
authors.initials: A
authors.lastname: Naszály
authors.forename: Arpád
authors.initials: A
authors.lastname: Mayer
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003679:Deglutition / Q000187:drug effects / Q000528:radiation effects; D003680:Deglutition Disorders / Q000209:etiology; D004334:Drug Administration Schedule; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D004941:Esophagitis / Q000209:etiology; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010166:Palliative Care / Q000379:methods; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant / Q000379:methods; D012074:Remission Induction; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D002945:Cisplatin; D005472:Fluorouracil